Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board

Former Danaher executive provides significant clinical, global market, and product development expertise in cancer diagnostics BERKELEY, CA –  MAINZ, Germany – November 18, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Soren Thestrup-Nielsen M.D. […]